Browsing Tag
PROACT 1
1 post
ProKidney (NASDAQ: PROK) stock surges over 22% after Phase 2 REGEN-007 trial shows strong kidney function stabilization
Find out why ProKidney stock soared 22% after new Phase 2 data on rilparencel in chronic kidney disease patients. Analysts see potential FDA fast-track.